Clinical setbacks for toll-like receptor 9 agonists in cancer

Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information



Related links

Related links

Related links in Nature Research

Toll-like receptor therapies compete to reduce side effects

Web links

Coley Pharmaceutical

Idera Pharmaceuticals




Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25, 825–826 (2007).

Download citation

Further reading


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing